Zhejiang Hisoar Pharmaceutical Co., Ltd. (SZSE: 002099)
Health Care · Pharmaceuticals · CN
CN¥5.24
-2.96% today · -13.2% 1Y
Zhejiang Hisoar Pharmaceutical Co., Ltd. (SZSE: 002099) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $1.22B and employs 2,736 people.
Over the last twelve months the share price has lost 13.2%, trading between 4.87 and 9.09.
Tweenvest scores Zhejiang Hisoar Pharmaceutical Co., Ltd. across four factors: quality 67/100, value 55/100, growth 0/100. Its strongest factor is quality.
002099 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.22B
- Revenue (TTM)
- $269.78M
- P/E
- —
- EPS
- -0.05
- Dividend yield
- —
- Beta (5Y)
- 0.32
- 52-week high
- CN¥9.09
- 52-week low
- CN¥4.87
- Avg volume (3M)
- —
- Shares outstanding
- 1.56B
- Employees
- 2,736
- Next earnings
- —
About Zhejiang Hisoar Pharmaceutical Co., Ltd.
Zhejiang Hisoar Pharmaceutical Co., Ltd. is a pharmaceutical enterprise that specializes in the manufacturing and global distribution of fine chemicals and specialized active pharmaceutical ingredients (APIs). Its diverse product portfolio encompasses materials used in the production of antibiotics, antiviral medications, cardiovascular drugs, and glucose-reducing agents, among others. Beyond these core APIs, the company also supplies pharmaceutical intermediates and provides customized processing services. Key products include clindamycin, the 4-AA Iso-carbapenem series, thiamphenicol, florfenicol, and voglibose. A significant portion of its output is destined for international markets through exports. Established in 1966, the company maintains its operational headquarters in Taizhou, China.
- ISIN
- CNE000001PY2
- Founded
- 1966
- Listed since
- Dec 26, 2006
- Exchange
- Shenzhen Stock Exchange
- Currency
- CNY
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,244.81 | -0.84% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $271.91 | +0.62% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $151.14 | -0.92% |
| Roche Holding AGSWX: ROP | $373.91B | CHF370.10 | -1.46% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £120.74 | -1.36% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.06 | -0.05% |
Figures last refreshed Aug 18, 2026.